Asset profile
ALN-PNP
Unknown / undisclosed
Evidence outlook · lead readout
NCT06024408 · Nonalcoholic Fatty Liver Disease (NAFLD), Nonalcoholic Steatohepatitis (NASH), Genetic Risk Factor
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT06024408: Participants were randomly assigned and neither they nor the study staff knew who received ALN-PNP versus placebo, which is a solid design. But only 9 people were enrolled and the trial's own findings have not yet been posted, so there is no result to judge yet.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.
2027 (1)
August 2027 (1)
What to watch
Research analysis
Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.
Sign in to access Research2030 (1)
March 2030 (1)
What to watch
Research analysis
Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.
Sign in to access ResearchAll registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.